The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sorokina N.D.

Evdokimov Moscow State University of Medicine and Dentistry

Pertsov S.S.

Anokhin Research Institute of Normal Physiology;
Evdokimov Moscow State University of Medicine and Dentistry

Selitsky G.V.

Evdokimov Moscow State University of Medicine and Dentistry

Zherdeva A.S.

Evdokimov Moscow State University of Medicine and Dentistry

Antiepileptic drugs in the treatment of migraine and neuropathic pain

Authors:

Sorokina N.D., Pertsov S.S., Selitsky G.V., Zherdeva A.S.

More about the authors

Journal: Russian Journal of Pain. 2021;19(3): 45‑52

DOI: 10.17116/pain20211903145

Views: 22992

Downloaded: 439

Download PDF (RU)
Contact the author
Table of contents

ANTIEPILEPTIC DRUGS IN THE TREATMENT OF MIGRAINE AND NEUROPATHIC PAIN
ANTIEPILEPTIC DRUGS IN THE TREATMENT OF MIGRAINE AND NEUROPATHIC PAIN

To cite this article:

Sorokina ND, Pertsov SS, Selitsky GV, Zherdeva AS. Antiepileptic drugs in the treatment of migraine and neuropathic pain. Russian Journal of Pain. 2021;19(3):45‑52. (In Russ.)
https://doi.org/10.17116/pain20211903145

Подписка 2025-2 (Russian Journal of Pain)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Medi­cation-overuse headache: description of patients and medi­cations used before admi­ssion to specialized center. Russian Journal of Pain. 2024;(2):16-21
Como­rbid diso­rders and risk factors for neiropathic pain in distal diabetic poly­neuropathy. Russian Journal of Pain. 2024;(2):41-48
Calcitonin gene-related peptide in pathophysiology of migraine. Russian Journal of Pain. 2024;(2):56-67
Preferable drugs for relief of migraine atta­cks and tension type headache in pregnant women. Russian Journal of Pain. 2024;(3):12-18
A comparative asse­ssment of microbiocenosis of saliva and oropharynx in patients with migraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):55-62
Features of course of pain syndrome in patients with schwannomatosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):48-52
The inte­nsity of neuropathic pain and the seve­rity of inso­mnia in diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):87-92
Sleep diso­rders in patients with medi­cation-overuse headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):93-98
Features of primary forms of headache in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73
Oxidative stress in the pathogenesis of chro­nic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40

Antiepileptic drugs (AED) are currently used for neuropathic pain and migraine along with other drugs. An efficacy of gabapentin and pregabalin for post-herpetic neuralgia and diabetic neuropathy, as well as divalproex sodium/sodium valproate and topiramate for prevention of migraine has led to expansion of clinical researches of new peptides for the treatment of these diseases. Levetiracetam and zonisamide are currently studied in multiple-center trials devoted to treatment and prevention of migraine. Oxcarbazepine, eslicarbazepine acetate, topiramate, zonisamide, levetiracetam, lacosamide, pregabalin are analyzed in treatment of neuropathic pain. There are interesting data on similar efficacy of zonisamide and topiramate for prevention of migraine, especially for those with a weak tolerance of topiramate. Levetiracetam is the simplest for administration and causes the least number of side effects. This review is devoted to some third-generation AED in the treatment of neuropathic pain and migraine.

Keywords:

migraine
neuropathic pain
antiepileptic drugs (AED)
mechanisms of action of AED

Authors:

Sorokina N.D.

Evdokimov Moscow State University of Medicine and Dentistry

Pertsov S.S.

Anokhin Research Institute of Normal Physiology;
Evdokimov Moscow State University of Medicine and Dentistry

Selitsky G.V.

Evdokimov Moscow State University of Medicine and Dentistry

Zherdeva A.S.

Evdokimov Moscow State University of Medicine and Dentistry

Received:

01.06.2021

Accepted:

05.07.2021

List of references:

  1. Vlasov PN. Prospects for the use of new antiepileptic drugs. Epilepsy and Paroxysmal Conditions. 2015;4:40-49. (In Russ.). https://doi.org/10.17749/2077-8333.2015.7.4.040-049
  2. Zarcone D, Corbetta S. Shared mechanisms of epilepsy, migraine and affective disorders. Neurological Sciences. 2017;38(1):73-76.  https://doi.org/10.1007/s10072-017-2902-0
  3. Sidhu HS, Sadhotra A. Current status of the new antiepileptic drugs in chronic pain. Frontiers in Pharmacology. 2016;7:276.  https://doi.org/10.3389/fphar.2016.00276
  4. Duko B, Ayalew M, Toma A. The epidemiology of headaches among patients with epilepsy: a systematic review and meta-analysis. The Journal of Headache and Pain. 2020;21:3.  https://doi.org/10.1186/s10194-020-1074-0
  5. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache: The Journal of Head and Face Pain. 2018;58(3):218-229.  https://doi.org/10.1111/head.13375
  6. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53(7):26-33.  https://doi.org/10.1111/j.1528-1167.2012.03712.x
  7. Dosenovic S, Kadic AJ, Miljanovic M. Interventions for neuropathic pain: an overview of systematic reviews. Anesth Analg. 2017;125(2):643-652.  https://doi.org/10.1213/ANE.0000000000001998.
  8. Perucca E. Antiepileptic drugs: evolution of our knowledgeand changes in drug trials. Epileptic Disord. 2019;21(4):319-329.  https://doi.org/10.1684/epd.2019.1083
  9. Abou-Khalil BW. Antiepileptic drugs. Continuum: Lifelong Learning in Neurology. 2016;22(1):132-156.  https://doi.org/10.1212/con.0000000000000289
  10. Sills GJ. Mechanisms of action of antiepileptic drugs. In: Rugg-Gunn F.J., Sander J.W., Smalls J.E., eds. Epilepsy 2011: From Sciences to Society. A Practical Guide to Epilepsy.13th Edition. International League Against Epilepsy: Chalfont St Peter.
  11. Parikh SK, Silberstein SD. Current status of antiepileptic drugs as preventive migraine therapy. Curr Treat Options Neurol. 2019;21:16.  https://doi.org/10.1007/s11940-019-0558-1
  12. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews. 2013;6.  https://doi.org/10.1002/14651858.CD010608
  13. Tabeeva GR., Katsarava Z. Modern concept of pathophysiology and new targets of migraine therapy. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):143-152. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-143-152
  14. Voronkova KV, Shevchenko AV, Pylaeva OA, Zykova OV. The use of antiepileptic drugs in medical practice. Russkij zhurnal detskoj nevrologii. 2009;4(1):27-43. (In Russ.).
  15. Buch D, Chabriat H. Lamotrigine in the prevention of migraine with aura: a narrative review. Affiliations Headache. 2019;59(8):1187-1197. https://doi.org/10.1111/head.13615
  16. Nevitt SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews. 2018;6:CD001031. https://doi.org/10.1002/14651858.CD001031.pub4
  17. Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache J Head Face Pain. 2017;57(1):165-178.  https://doi.org/10.1111/head.12997
  18. Avakyan GN, Belousova ED, Burd SG, et al. Problems of epileptology. Key priorities, tasks, challenges and ways to solve them. Epilepsy and Paroxysmal Conditions. 2019;11(4):395-406. (In Russ.). https://doi.org/10.17749/2077-8333.2019.11.4.395-406
  19. Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;12;70(7):548-555.  https://doi.org/10.1212/01.wnl.0000297551.27191.70
  20. Sprenger T, Viana M, Tassorelli C. Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. Neurotherapeutics. 2018;15:1-323.  https://doi.org/10.1007/s13311-018-0621-8
  21. Shank RP, Doose DR, Streeter AJ, Bialer M. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res. 2005;63(2-3):103-112. 
  22. Durham PL, Niemann C, Cady R. Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache. 2006;46(8):1291-1295.
  23. Garcia-Estevez DA, Pardo-Parrado M, Silvarrey-Rodriguez S. Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide. Rev Neurol. 2017;65(4):153-156. 
  24. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9:175-85.  https://doi.org/10.1111/j.1526-4637.2007.00389.x
  25. Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008;14:120-142.  https://doi.org/10.1111/j.1527-3458.2008.00041.x
  26. Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85:283-288. 
  27. Silberstein SD. Topiramate in migraine prevention. Headache. 2005;45(1):57-65.  https://doi.org/10.1111/j.1526-4610.2005.4501005.x
  28. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;2013(6):1-84.  https://doi.org/10.1002/14651858.CD010610
  29. Bektas N, Arslan R, Ozturk Y. Zonisamide: antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy. Life Sci. 2014;95(1):9-13.  https://doi.org/10.1016/j.lfs.2013.12.012
  30. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis. Clin Neuropharmacol. 2011;34(4):174-177.  https://doi.org/1010.1097/WNF.0b013e318225140c
  31. Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013;33:101-111.  https://doi.org/10.1177/0333102412466968
  32. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis o fepisodic migraine in adults. Cochrane Database Syst Rev. 2013;6:1-50.  https://doi.org/10.1002/14651858.CD010609
  33. Perloff MD, Berlin RK, Gillette M, Petersile MJ, Kurowski D. Gabapentin in headache disorders: what is the evidence? Pain Med. 2016;17(1):162-171.  https://doi.org/10.1111/pme.12931
  34. Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial ofgabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013;33:101-111.  https://doi.org/10.1177/0333102412466968
  35. Hesami O, Shams MR, Ayazkhoo L, et al. Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study. Iran J Pharm Res IJPR. 2018;17(2):783-789. 
  36. Osipova VV, Filatova EG, Artemenko AR, et al. Brief recommendations of Russian experts on the diagnosis and treatment of migraine. Russkij meditsinskij zhurnal. 2017;9:556-562. (In Russ.).
  37. Verma A, Srivastava D, Kumar A, Singh V. Levetiracetam in migraine prophylaxis. Clin Neuropharmacol. 2013;36:193-197.  https://doi.org/10.1097/WNF.0000000000000005
  38. Sadeghian H, Motiei-Langroudi R. Comparison of Levetiracetam and sodium valproate in migraine prophylaxis: a randomized placebo-controlled study. Ann Indian Acad Neurol. 2015;18:45-48.  https://doi.org/10.4103/0972-2327.144290
  39. Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol. 2006;29:338-342.  https://doi.org/10.1097/01.WNF.0000236766.08409.03
  40. Verma A, Srivastava D, Kumar A, Singh V. Levetiracetam in migraine prophylaxis. Clin Neuropharmacol. 2013;36:193-197.  https://doi.org/10.1097/WNF.0000000000000005
  41. Watkins AK, Gee ME, Brown JN. Efficacy and safety of levetiracetam for migraine prophylaxis: a systematic review. J Clin Pharm Ther. 2018;43:467-475.  https://doi.org/10.1111/jcpt.12715
  42. Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. Cephalalgia. 2011;31:530-536.  https://doi.org/10.1177/0333102410384886
  43. Kashipazha D, Ghadikolaei HSh, Siavashi M. Levetiracetam in compare to sodium valproate for prophylaxis in chronic migraine headache: a randomized double-blind clinical trial. Curr Clin Pharmacol. 2017;12(1):55-59.  https://doi.org/10.2174/1574884712666170329094419
  44. Tommaso M, Guido M, Sardaro M, et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neurosci Lett. 2008;442:81-85.  https://doi.org/10.1016/j.neulet.2008.06.076
  45. Sadeghian H, Motiei-Langroudi R. Comparison of Levetiracetam and sodium valproate in migraine prophylaxis: a randomized placebo-controlled study. Ann Indian Acad Neurol. 2015;18:45-48.  https://doi.org/10.4103/0972-2327.144290
  46. Bootsma HPR, Ricker L, Diepman L, Gehring J, et al. Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure. 2008;17:19-26.  https://doi.org/10.1016/j.seizure.2007.05.019
  47. Yen PH, Kuan YC, Tam KW, et al. Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis. J Formos Med Assoc. 2021;120(1):755-764.  https://doi.org/10.1016/j.jfma.2020.08.020
  48. Tsaousi G, Pourzitaki Ch, Siafis S, et al. Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative. Eur J Clin Pharmacol. 2020;76(2):161-174.  https://doi.org/10.1007/s00228-019-02790-2
  49. Yogeeswari P, Vaigunda Ragavendran J, Sriram D. Neuropathic pain: strategies in drug discovery and treatment. Expert Opin Drug Discov. 2007;2:169-184.  https://doi.org/10.1517/17460441.2.2.169
  50. Yakhno NN, Kukushkin ML, Danilov AB, et al. The results of the Russian epidemiological study of the prevalence of neuropathic pain, its causes and characteristics in the population of outpatient patients who turned to a neurologist. Pain. 2008;3(20):24-32. (In Russ.).
  51. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. 2010. https://doi.org/10.1002/14651858.CD001133.pub3
  52. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;16;3:17002. https://doi.org/10.1038/nrdp.2017.2
  53. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53(7):26-33.  https://doi.org/10.1111/j.1528-1167.2012.03712.x
  54. Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain Sascha R.A. Pharmacol Rev. 2018;70:315-347.  https://doi.org/doi.org/10.1124/pr.117.014399
  55. Goodyear-Smith F, Halliwell J. Anticonvulsants for neuropathic pain: gaps in the evidence. Clin J Pain. 2009;25:528-536.  https://doi.org/10.1097/AJP.0b013e318197d4cc
  56. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. 2005;3:CD001133. PMID: 16034857. https://doi.org/10.1002/14651858.CD001133.pub2
  57. Guay DRP. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: Potential use in neuropathic pain. The American Journal of Geriatric Pharmacotherapy. 2003;1(1):18-38.  https://doi.org/10.1016/s1543-5946(03)80013-2
  58. Finnerup NB, Attal N, Haroutounian S. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.  https://doi.org/10.1016/S1474-4422(14)70251-0
  59. Davydov OS. Antiepileptic drugs beyond epilepsy (the use of anticonvulsants in the treatment of pain syndromes). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;4:58-65. (In Russ.).
  60. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;5(2):14-17.  https://doi.org/10.1212/wnl.59.5_suppl_2.s14
  61. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013;36:237-251.  https://doi.org/10.1007/s12272-013-0057-y
  62. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ-1 calcium channel subunit in neuropathic pain. Pharmacology Research & Perspectives. 2016;4(2):e00205. PMID: 27069626. https://doi.org/10.1002/prp2.205
  63. Kumar N, Cherkas PS, Varathan V, et al. Systemic pregabalin attenuates facial hypersensitivity and noxious stimulus evoked release of glutamate in medullary dorsal horn in a rodent model of trigeminal neuropathic pain. Neurochem. Int. 2013;62:831-835.  https://doi.org/10.1016/j.neuint.2013.02.022
  64. Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2017;6:CD007938. https://doi.org/10.1002/14651858.CD007938.pub4
  65. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain Journal. 2010;150(3):573-581.  https://doi.org/10.1016/j.pain.2010.06.019
  66. Onakpoya IJ, Thomas ET, Lee JJ, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;9(1):e023600. https://doi.org/10.1136/bmjopen-2018-023600
  67. Davari M, Amani B, Khanijahani A, et al. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. Korean J Pain. 2020;33(1):3-12.  https://doi.org/10.3344/kjp.2020.33.1.3
  68. Derry Sh, Bell RF, Straube S. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):CD007076. https://doi.org/10.1002/14651858.CD007076.pub3
  69. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;8(3):CD007076. https://doi.org/10.1002/14651858.CD007076.pub2
  70. Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017;12(12):CD007963. https://doi.org/10.1002/14651858.CD007963.pub3
  71. Montero AA, Carnerero CS. Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: Evidence and experience. Neurologia. 2019;34(6):386-395.  https://doi.org/10.1016/j.nrl.2016.11.009
  72. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;2:CD009318. https://doi.org/10.1002/14651858.CD009318.pub2
  73. Abd-Elsayed A, Jackson M, Gu SL, Fiala K, Gu J. Neuropathic pain and Kv7 voltage-gated potassium channels: the potential role of Kv7 activators in the treatment of neuropathic pain. Mol Pain. 2019;15:1744806919864256. https://doi.org/10.1177/1744806919864256
  74. De Greef BTA, Hoeijmakers JGJ, Geerts M. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain. 2019;142(2):263-275.  https://doi.org/10.1093/brain/awy329
  75. Parfenov VA, Yakhno NN, Davydov OS, et al. Discogenic lumbosacral radiculopathy. Recommendations of the Russian Association for the Study of Pain (RSSP). Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):15-24. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-15-24
  76. https://doi.org/10.25731/RASP.2018.04.025  https://doi.org/10.25731/RASP.2018.04.025

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.